0IGA Stock Overview
A life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Emergent BioSolutions Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.06 |
| 52 Week High | US$15.10 |
| 52 Week Low | US$3.88 |
| Beta | 2.09 |
| 1 Month Change | 13.76% |
| 3 Month Change | -52.84% |
| 1 Year Change | 22.07% |
| 3 Year Change | -84.60% |
| 5 Year Change | -91.24% |
| Change since IPO | -90.04% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0IGA | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -5.7% | 13.0% | 2.1% |
| 1Y | 22.1% | -13.9% | 2.2% |
Return vs Industry: 0IGA exceeded the UK Biotechs industry which returned -13.9% over the past year.
Return vs Market: 0IGA exceeded the UK Market which returned 2.2% over the past year.
Price Volatility
| 0IGA volatility | |
|---|---|
| 0IGA Average Weekly Movement | 12.1% |
| Biotechs Industry Average Movement | 9.0% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in GB Market | 10.8% |
| 10% least volatile stocks in GB Market | 3.1% |
Stable Share Price: 0IGA's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0IGA's weekly volatility has decreased from 18% to 12% over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 900 | Joe Papa | www.emergentbiosolutions.com |
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; Botulism Antitoxin Heptavalent for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Trobigard, an atropine sulfate obidoxime chloride auto-injector.
Emergent BioSolutions Inc. Fundamentals Summary
| 0IGA fundamental statistics | |
|---|---|
| Market cap | US$279.29m |
| Earnings (TTM) | -US$190.60m |
| Revenue (TTM) | US$1.04b |
0.3x
P/S Ratio-1.4x
P/E RatioIs 0IGA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0IGA income statement (TTM) | |
|---|---|
| Revenue | US$1.04b |
| Cost of Revenue | US$668.20m |
| Gross Profit | US$375.40m |
| Other Expenses | US$566.00m |
| Earnings | -US$190.60m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 07, 2025
| Earnings per share (EPS) | -3.51 |
| Gross Margin | 35.97% |
| Net Profit Margin | -18.26% |
| Debt/Equity Ratio | 137.5% |
How did 0IGA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/05 05:17 |
| End of Day Share Price | 2025/05/05 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Emergent BioSolutions Inc. is covered by 16 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Robert Wasserman | Benchmark Company |
| Mario Corso | Caris & Company |